Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs RARE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RARE Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

RARE Overall Winner 6-Pillar Tally: RGNX 3 – 3 RARE Matrix Metrics: RGNX 3 – 6 RARE

As of Nov 16, 2026, Ultragenyx Pharmaceutical Inc. (RARE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RARE carries 43.8/100 (HOLD) at $15.96 (11.2x Forward P/E, -59.9% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. RARE 43.8/100 HOLD), RARE captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-59.9% vs. -120.4% operating margin) and revenue trajectory (+8.1% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs RARE
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
RARE NASDAQ Head-to-Head Winner
Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations
$15.96
-0.72% 1D
Market Cap $1.7B
TTM Revenue $730M
Forward P/E 11.2x
Beta / 30D Vol 1.41β · 58% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 36.0 Fund 53.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -18.7%) with fading momentum, RSI 48
RSI-14: 48.2 · SMA20: $16.26 · SMA50: $15.30

6-Pillar Scorecard Institutional Category Breakdown (RGNX 3 – 3 RARE)

Columns: Metric · RGNX · RARE
1. Valuation Multiples RARE
Forward P/E N/M 11.2x
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 2.3x
2. Growth & Scale RARE
Revenue Growth (YoY) -69.2% +8.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M $730M
Market Cap $500.9M $1.7B
3. Profitability & Quality RARE
Gross Margin -64.5% -10.7%
Operating Margin -120.4% -59.9%
Net Profit Margin -113.9% -71.8%
Return on Equity (ROE) -113.2% -608.5%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$447M
Cash Flow Margin -100.6% -61.2%
Net Cash / Leverage $29M Net Cash -608.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 171.9% (38th %ile)
Put/Call OI Skew N/A 0.40x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) 49.2% of Rev ($359M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (3) vs RARE (6)
Institutional Metric RGNX RARE Criterion Row Edge
Market Capitalization
Scale
$500.9M $1.7B Larger Scale RARE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 11.2x Lower Multiple RARE
Revenue Growth (YoY)
Growth
-69.2% +8.1% Higher Growth RARE
Operating Margin (TTM)
Profitability
-120.4% -59.9% Higher Margin RARE
Net Profit Margin
Profitability
-113.9% -71.8% Higher Margin RARE
Return on Equity (ROE)
Capital Efficiency
-113.2% -608.5% Higher ROE RGNX
52-Week Range Position
Momentum
19% ($5–$16) 12% ($13–$40) Stronger Trend RGNX
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.41β · 58% Vol Lower Realized Risk RARE
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M $730M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% -10.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$447M (-608.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RARE +1.93 pp
RGNX: +7.87% · RARE: +9.8%
3M Horizon RGNX +4.85 pp
RGNX: -32.52% · RARE: -37.37%
6M Horizon RGNX +66.21 pp
RGNX: +32.21% · RARE: -34.0%
1Y Horizon RGNX +15.65 pp
RGNX: -35.82% · RARE: -51.47%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue RARE Revenue RGNX Op. Margin RARE Op. Margin Margin Leader
FY2018 $220M $50M 40.3% -721.2% RGNX
FY2019 $40M $100M -422.9% -409.0% RARE
FY2020 $150M $270M -77.1% -121.8% RGNX
FY2021 $470M $350M 34.0% -108.6% RGNX
FY2022 $110M $360M -233.2% -178.6% RARE
FY2023 $90M $430M -297.1% -131.1% RARE
FY2024 $80M $560M -280.0% -95.7% RARE
FY2025 $170M $670M -94.6% -79.5% RARE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RARE BREAKDOWN
93d in phase · OBV DISTRIBUTION
Current IV 171.9%
IV Percentile 38th %ile
Put/Call OI Skew 0.40x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact RARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
RARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -59.9% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($359M)
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs RARE Key Questions & Quantitative Answers

As of Nov 16, 2026, Ultragenyx Pharmaceutical Inc. (RARE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas RARE carries 43.8/100 (HOLD) at $15.96 (11.2x Forward P/E, -59.9% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. RARE 43.8/100 HOLD), RARE captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-59.9% vs. -120.4% operating margin) and revenue trajectory (+8.1% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RARE leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with RARE at +8.1% YoY revenue growth and +0.0% YoY earnings growth on $730M TTM revenue (-10.7% gross margin, -59.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while RARE shifted +1240.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($359M) (0 disclosures) for RARE.

RARE screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas RARE trades at 11.2x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-61.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus RARE (-608.5% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, RARE carries 171.9% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.